|
1.
|
原著(症例報告除く)
|
Japanese translation of the Functional Assessment of Cancer Therapy-Breast + 4 (FACT-B + 4) following international guidelines: a verification of linguistic validity. 2025/07
|
|
2.
|
原著(症例報告除く)
|
Validation of the Symptom Illustration Scale within an electronic Patient-Reported Outcomes Monitoring environment for metastatic breast cancer patients undergoing chemotherapy 2025/07
|
|
3.
|
原著(症例報告除く)
|
A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy 2025/05
|
|
4.
|
原著(症例報告除く)
|
Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia? 2025/05
|
|
5.
|
原著(症例報告除く)
|
Repeated sentinel lymph node biopsy for local recurrence after breast-conserving surgery 2025/05
|
|
6.
|
原著(症例報告除く)
|
An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42 2025/04
|
|
7.
|
症例報告
|
Double heterozygosity for BRCA1 and BRCA2 in breast cancer: considerations in surveillance and cancer risk management. 2025/04
|
|
8.
|
原著(症例報告除く)
|
Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors 2025/04
|
|
9.
|
原著(症例報告除く)
|
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer 2025/02
|
|
10.
|
原著(症例報告除く)
|
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE) 2025/01
|
|
11.
|
原著(症例報告除く)
|
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors 2024/12
|
|
12.
|
原著(症例報告除く)
|
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial) 2024/11
|
|
13.
|
総説
|
Prospective surveillance and early intervention to prevent chronic breast cancer-related arm lymphedema-what are the barriers? 2024/11
|
|
14.
|
総説
|
Quality of life issues in patients with ductal carcinoma in situ: a systematic review 2024/10
|
|
15.
|
原著(症例報告除く)
|
Updates on the preventions and management of post-mastectomy pain syndrome beyond medical treatment: a comprehensive narrative review 2024/09
|
|
16.
|
その他
|
【乳癌学2024(下)-最新の診断と治療-】フォローアップとトータルヘルスケア 乳癌診療におけるQOL/PRO評価 2024/09
|
|
17.
|
原著(症例報告除く)
|
Eribulin versus S-1 as fi rst or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a noninferiority, randomised, controlled, open-label, phase 3 trial 2024/07
|
|
18.
|
総説
|
Statistical Analysis Methods and Reporting of Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan: A Systematic Review 2024/05
|
|
19.
|
症例報告
|
Appendiceal Metastasis of Breast Cancer: A Case Report and a Literature Review 2024/04
|
|
20.
|
原著(症例報告除く)
|
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing 2024/04
|
|
21.
|
原著(症例報告除く)
|
Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy 2024/03
|
|
22.
|
原著(症例報告除く)
|
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale 2024/03
|
|
23.
|
原著(症例報告除く)
|
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer 2024/01
|
|
24.
|
原著(症例報告除く)
|
De-differentiation in cultures of organoids from luminal-type breast cancer is restored by inhibition of NOTCH signaling 2023/11
|
|
25.
|
原著(症例報告除く)
|
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition 2023/11
|
|
26.
|
原著(症例報告除く)
|
Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer 2023/09
|
|
27.
|
症例報告
|
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis 2023/07
|
|
28.
|
原著(症例報告除く)
|
Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy 2023/03
|
|
29.
|
原著(症例報告除く)
|
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials 2022/10
|
|
30.
|
原著(症例報告除く)
|
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study 2022/09
|
|
31.
|
原著(症例報告除く)
|
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. 2022/04
|
|
32.
|
原著(症例報告除く)
|
Cancer patient satisfaction with health care professional communication. An international EORTC study 2021/09
|
|
33.
|
原著(症例報告除く)
|
Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer 2021/09
|
|
34.
|
その他
|
【10年後の乳がん診療】乳がん薬物療法におけるQOL評価 2021/09
|
|
35.
|
原著(症例報告除く)
|
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. 2021/05
|
|
36.
|
症例報告
|
IgG4関連疾患疑診群の1例 2021/03
|
|
37.
|
原著(症例報告除く)
|
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC 2021/01
|
|
38.
|
原著(症例報告除く)
|
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. 2021
|
|
39.
|
原著(症例報告除く)
|
Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study 2020/12
|
|
40.
|
その他
|
【性ホルモンと産生・依存性腫瘍の基礎と臨床】性ホルモン依存性悪性腫瘍 エストロゲンと乳癌 乳癌の発生から最新分子標的治療まで 2020/06
|
|
41.
|
原著(症例報告除く)
|
The efficacy of sequential second‑line endocrine therapies (ETs) in postmenopausal estrogen receptor‑positive and HER2‑negative metastatic breast cancer patients with lower sensitivity to initial ETs 2020/05
|
|
42.
|
原著(症例報告除く)
|
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial 2020/02
|
|
43.
|
原著(症例報告除く)
|
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer 2020
|
|
44.
|
原著(症例報告除く)
|
Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy. 2019/07
|
|
45.
|
原著(症例報告除く)
|
Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study. 2019/03
|
|
46.
|
原著(症例報告除く)
|
Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan 2019/01
|
|
47.
|
原著(症例報告除く)
|
Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports. 2018/10
|
|
48.
|
原著(症例報告除く)
|
Hormonal Therapy Resistant Estrogen-receptor Positive Metastatic Breast Cancer Cohort (HORSE-BC) Study : Current Status of Treatment Selection in Japan. 2018/08
|
|
49.
|
原著(症例報告除く)
|
Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. 2017/07
|
|
50.
|
原著(症例報告除く)
|
Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey. 2017/04
|
|
51.
|
原著(症例報告除く)
|
Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. 2016/11
|
|
52.
|
原著(症例報告除く)
|
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. 2015/09
|
|
53.
|
症例報告
|
Angiosarcoma of the Breast – specific findings of MRI 2006
|
|
5件表示
|
|
全件表示(53件)
|
